Analysis of RGS2 expression and prognostic significance in stage II and III colorectal cancer
Analysis of RGS2 expression and prognostic significance in stage II and III colorectal cancer
复制标题
DOI：
10.1042/bsr20090129
复制
发表时间：
2010-12-01
影响因子：
4
通讯作者：
Cai, Sanjun
中科院分区：
文献类型：
--
作者：
Jiang, Zheng;Wang, Zhimin;Cai, Sanjun
RGS 2（G蛋白信号传导调节因子2）的作用已在几种肿瘤中进行了研究。本研究旨在探讨II期和III期结直肠癌患者的临床病理因素与患者生存时间和RGS 2表达之间的相关性。采用实时荧光定量PCR方法检测36例复发和28例未复发的结直肠癌组织中RGS 2 mRNA的表达，并检测3株转移癌细胞系（SW 620、LoVo和Colo 205）和3株原发癌细胞系（SW 480、Caco-2和HCT 116）中RGS 2 mRNA的表达。此外，为了提供RGS 2 mRNA表达的可视化证据，还用RT-PCR（逆转录-PCR）对随机CRC样品进行了检测。采用免疫组化法检测118例胃癌组织中RGS 2蛋白的表达，分析RGS 2表达与临床病理因素、生存时间的关系。我们发现RGS 2 mRNA在复发和转移来源的细胞系中均下调，并且RGS 2的表达水平与性别、年龄、肿瘤分级、淋巴管或神经周围浸润无关。但与无病生存期呈正相关（P < 0.05）。此外，RGS 2低表达表示较差的存活率（P < 0.05，对数秩检验）。多因素分析显示RGS 2蛋白表达减弱是大肠癌的独立危险因素（P < 0.05）。综上所述，我们认为RGS 2的下调可能在结直肠癌转移中起重要作用，并预测II期和III期结直肠癌患者的不良预后。
The role of RGS2 (regulator of G-protein signalling 2) has been studied in several tumours. The purpose of the present study is to investigate the correlations between clinicopathological factors and patients' survival time and RGS2 expression in stage II and III CRC (colorectal cancer) patients. Real-time quantitative PCR was performed in 36 CRC tissues with recurrence and 28 without recurrence, and in three CRC-metastasis-derived cell lines (SW620, LoVo and Colo205) and 3 primary-CRC-derived ones (SW480, Caco-2 and HCT116) to examine RGS2 mRNA expression. In addition, to provide visualized evidence for RGS2 mRNA expression, random CRC samples were also performed with RT-PCR (reverse transcription-PCR). RGS2 protein was detected by immunostaining in 118 paraffin-embedded specimens, and the correlations between clinicopathological factors and survival time and RGS2 expression were analysed. We found that RGS2 mRNA was down-regulated both in CRC tissues with recurrence and metastasis-derived cell lines, and the expression level of RGS2 was unrelated to gender, age, tumour grade, or lymphovascular or perineural invasion. However, it was positively related to disease-free survival time (P < 0.05). Furthermore, low RGS2 expression indicated a poorer survival rate (P < 0.05, log-rank test). Multivariate analysis also showed that weak RGS2 protein expression was an independent adverse prognosticator in CRC (P < 0.05). Taken together, we suggested that down-regulation of RGS2 might play an important role in CRC metastasis and predict poor prognosis in stage II and III CRC patients.